Twin Focus Capital Partners’s TherapeuticsMD TXMD Stock Holding History

Twin Focus Capital Partners’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-12,704	Closed	-$673K	–	173
2020 Q1	$673K	Buy	12,704 +2,000	+19%	+$198K	0.31%	55
2019 Q4	$1.29M	Hold	10,704	–	–	0.42%	44
2019 Q3	$1.94M	Buy	+10,704	New	+$1.51M	0.76%	26
2018 Q3	–	Sell	-600	Closed	-$187K	–	111
2018 Q2	$187K	Buy	+600	New	+$183K	0.1%	106

Other funds holding TXMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Twin Focus Capital Partners's TXMD Position: Q2 2020 in Review

Twin Focus Capital Partners sold out of TherapeuticsMD (TXMD) in Q2 2020, closing a stake of 12,704 shares — an estimated $673K sold.

Twin Focus Capital Partners first reported a position in TXMD in Q2 2018 and held it in 4 quarters. The position peaked at $1.94M in Q3 2019. 149 funds tracked by Wall St. Rank hold TXMD as of Q2 2020.

Twin Focus Capital Partners reported no remaining TherapeuticsMD position as of Q2 2020 after selling out during the quarter.
Twin Focus Capital Partners sold 12,704 TherapeuticsMD shares in Q2 2020, an estimated $673K.
Twin Focus Capital Partners first reported a position in TherapeuticsMD in Q2 2018 and held it in 4 quarters.
Twin Focus Capital Partners's TherapeuticsMD position peaked at $1.94M in Q3 2019.
149 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2020.

Based on Twin Focus Capital Partners's 13F filing for Q2 2020, filed 12 Aug 2020.